Literature DB >> 190537

Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme.

D B Case, J M Wallace, H J Keim, M A Weber, J E Sealey, J H Laragh.   

Abstract

To block renin activity, a nonapeptide converting-enzyme inhibitor was given to 65 seated hypertensive patients. Depressor responses occurred only when control plasma renin activity exceeded 2 ng of angiotensin I per milliliter per hour and correlated directly in amplitude with control plasma renin activity and with induced increments in activity (P less than 0.001 for both). Depressor responses, like renin activity, were characteristic for renin subgroups as defined by renin-sodium profiling. Before and after sodium deprivation, the nonapeptide reduced diastolic pressure in all patients with high renin (by 17.3 and 19.8 per cent) and most patients with normal renin (by 9.1 and 17.7 per cent). Low-renin patients remained unresponsive. This enzyme blockade may cause bradykinin accumulation. But if, as seems likely, depressor responses are due to blockade of angiotensin II formation, the results indicate that, irrespective of sodium balance, measurements of plasma renin activity reflect its contribution to blood-pressure maintenance. The results suggest broad participation of the renin system in common forms of hypertension.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 190537     DOI: 10.1056/NEJM197703242961201

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  36 in total

1.  Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension.

Authors:  Stephen T Turner; Gary L Schwartz; Arlene B Chapman; Amber L Beitelshees; John G Gums; Rhonda M Cooper-DeHoff; Eric Boerwinkle; Julie A Johnson; Kent R Bailey
Journal:  Am J Hypertens       Date:  2010-08-19       Impact factor: 2.689

2.  Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers.

Authors:  M de Gasparo; F Cumin; J Nussberger; T T Guyenne; J M Wood; J Menard
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

Review 3.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

4.  Augmenting Renal Lymphatic Density Prevents Angiotensin II-Induced Hypertension in Male and Female Mice.

Authors:  Dakshnapriya Balasubbramanian; Catalina A Lopez Gelston; Alexandra H Lopez; Geina Iskander; Winter Tate; Haley Holderness; Joseph M Rutkowski; Brett M Mitchell
Journal:  Am J Hypertens       Date:  2020-01-01       Impact factor: 2.689

Review 5.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

6.  Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.

Authors:  A A Ajayi; N Hockings; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

7.  Escherichia coli mutants defective in dipeptidyl carboxypeptidase.

Authors:  C E Deutch; R L Soffer
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

8.  Reversal of renovascular hypertension by antibodies specific for angiotensin-converting enzyme.

Authors:  R A Markle; E H Sonnenblick; J M Conroy; R L Soffer
Journal:  Proc Natl Acad Sci U S A       Date:  1978-11       Impact factor: 11.205

9.  The adrenal receptor for angiotensin II is altered in essential hypertension.

Authors:  G H Williams; N K Hollenberg; T J Moore; S L Swartz; R G Dluhy
Journal:  J Clin Invest       Date:  1979-03       Impact factor: 14.808

10.  Fate of bradykinin-potentiating peptide 9a after intravenous injection.

Authors:  L C Martin; J W Ryan; G H Fisher; A Chung; M Epstein; J M Stewart
Journal:  Biochem J       Date:  1979-12-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.